APG-115
Phase 2Small molecule
Ascentage Pharma Group Inc.APG-115 is one of 116 small molecule programs targeting Malignant Salivary Gland Cancer. It is currently in Phase 2.
6
Indications
8
Total Trials
6
Active Trials
115
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
88 competitors in Neuroblastoma
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Phase 3
Vepesid
AAvyxa
Phase 3
Paraplatin
AAvyxa
Phase 3
Leukine
SanofiPhase 3
Camptosar
PfizerPhase 3
Tepadina
Jazz PharmaceuticalsPhase 3
Alkeran
AApotex Inc.
Phase 3
Accutane
CConrado Roberto Hoffmann Filho
Phase 3
Adriamycin
PfizerPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Phase IB1 trial
Liposarcoma1 trial
3 more indications
Neuroblastoma1 trial
Malignant Salivary Gland Cancer1 trial
A Multicenter Phase I/II Trial of a Novel MDM2 Inhibitor (APG-115) in p53 Wild-type Salivary Gland Carcinoma
Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Preclinical·NCT03781986·41 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for APG-115. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company